DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
Nada BožinaIvan BilićLana GanociLivija ŠimičevićStjepko PleštinaLucija LešnjakovićVladimir TrkuljaPublished in: British journal of clinical pharmacology (2021)
DPYD c.496A>G and possibly c.2194G>A variants might need to be considered for inclusion in the DPYD genotyping panel.